Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
MyoKardia, Inc. (MYOK)
|
Add to portfolio |
|
|
|
| Price: |
$222.81
| | Metrics |
| OS: |
53.3
|
M
| |
-33
|
% ROE
|
| Market cap: |
$11.9
|
B
| |
-83
|
% ROIC
|
|
Net cash:
|
$896
|
M
| |
$16.80
|
per share
|
|
EV:
|
$11
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($280)
|
M
| |
|
|
|
EBIT
|
($283)
|
M
| |
|
|
| EPS |
($5.68)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 |
| Revenues | 0.0 | 33.6 | 11.4 | 42.0 | 14.2 | 5.9 | 0.0 |
| Revenue growth | -100.0% | 193.3% | -72.7% | 195.6% | 140.0% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 33.6 | 11.4 | 42.0 | 14.2 | 5.9 | 0.0 |
| Gross margin | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Selling, general and administrative | 61.7 | 38.4 | 22.0 | | | | |
| Research and development | 146.2 | 68.8 | 48.1 | 36.2 | 28.4 | 18.3 | 11.6 |
| General and administrative | | | | 16.3 | 9.0 | 4.8 | 2.0 |
| EBIT | -287.8 | -73.7 | -58.7 | -10.5 | -23.2 | -17.2 | -13.6 |
| EBIT margin | | -219.5% | -512.7% | -25.1% | -163.5% | -291.0% | |
| Pre-tax income | -276.2 | -67.7 | -57.0 | -10.4 | -22.9 | -16.8 | -12.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -276.2 | -67.7 | -57.0 | -10.4 | -28.2 | -19.9 | -14.0 |
| Net margin | | -201.7% | -498.3% | -24.7% | -198.6% | -335.5% | |
| |
| Diluted EPS | ($6.17) | ($1.76) | ($1.74) | ($0.37) | ($4.48) | ($11.30) | ($11.98) |
| Shares outstanding (diluted) | 44.8 | 38.4 | 32.8 | 28.1 | 6.3 | 1.8 | 1.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|